| Literature DB >> 30911113 |
Billy Michael Chelliah Jebaraj1, Eugen Tausch1, Dan A Landau2,3,4, Jasmin Bahlo5, Sandra Robrecht5, Amaro N Taylor-Weiner6, Johannes Bloehdorn1, Annika Scheffold1, Daniel Mertens1,7, Sebastian Böttcher8,9, Michael Kneba8, Ulrich Jäger10, Thorsten Zenz1,11, Michael K Wenger12, Guenter Fingerle-Rowson12, Clemens Wendtner13, Anna-Maria Fink5, Catherine J Wu6, Barbara Eichhorst5, Kirsten Fischer5, Michael Hallek5, Hartmut Döhner1, Stephan Stilgenbauer14.
Abstract
Telomere length in chronic lymphocytic leukemia (CLL) has been shown to be of prognostic importance, but the analyses have largely been executed on heterogeneous patient cohorts outside of clinical trials. In the present study, we performed a comprehensive analysis of telomere length associations in the well characterized CLL8 trial (n = 620) of the German CLL study group, with validation in a representative cohort of the CLL4 trial (n = 293). Absolute telomere length was analyzed using quantitative-PCR. Apart from identifying associations of short telomere length with adverse prognostic factors and survival, the study identified cases with 17p- and 11q- associated with TP53 and ATM loss, respectively, to have the shortest telomeres, even when these aberrations were present in small subclones. Thus, telomere shortening may precede acquisition of the high-risk aberrations, contributing to disease evolution. In line with this, telomere shortening was associated with an increase in genomic complexity as well as clonal evolution, highlighting its importance as a biomarker especially in monitoring disease progression in non-high-risk CLL.Entities:
Mesh:
Year: 2019 PMID: 30911113 PMCID: PMC6737251 DOI: 10.1038/s41375-019-0446-4
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528